WO2010040062A3 - Réactifs de marquage de nanoparticules et leurs procédés d’utilisations - Google Patents

Réactifs de marquage de nanoparticules et leurs procédés d’utilisations Download PDF

Info

Publication number
WO2010040062A3
WO2010040062A3 PCT/US2009/059394 US2009059394W WO2010040062A3 WO 2010040062 A3 WO2010040062 A3 WO 2010040062A3 US 2009059394 W US2009059394 W US 2009059394W WO 2010040062 A3 WO2010040062 A3 WO 2010040062A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
labeling reagents
nanoparticle labeling
labeling
nanoparticle
Prior art date
Application number
PCT/US2009/059394
Other languages
English (en)
Other versions
WO2010040062A2 (fr
Inventor
Kevin C. Weng
Original Assignee
Advanced Throughput Ltd.Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Throughput Ltd.Co. filed Critical Advanced Throughput Ltd.Co.
Priority to US13/122,397 priority Critical patent/US20110236957A1/en
Publication of WO2010040062A2 publication Critical patent/WO2010040062A2/fr
Publication of WO2010040062A3 publication Critical patent/WO2010040062A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant le marquage de cibles biologiques mettant en œuvre un conjugué d’un composant luminescent et une molécule de ciblage fixés à une structure de noyau d’une nanoparticule. Les conjugués de marquage assurent un arrière-plan de haute et de faible intensité, et sont idéaux pour l’histologie et la pathologie.
PCT/US2009/059394 2008-10-02 2009-10-02 Réactifs de marquage de nanoparticules et leurs procédés d’utilisations WO2010040062A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/122,397 US20110236957A1 (en) 2008-10-02 2009-10-02 Nanoparticle Labeling Reagents and Methods of Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19517608P 2008-10-02 2008-10-02
US61/195,176 2008-10-02

Publications (2)

Publication Number Publication Date
WO2010040062A2 WO2010040062A2 (fr) 2010-04-08
WO2010040062A3 true WO2010040062A3 (fr) 2010-05-27

Family

ID=41463125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059394 WO2010040062A2 (fr) 2008-10-02 2009-10-02 Réactifs de marquage de nanoparticules et leurs procédés d’utilisations

Country Status (2)

Country Link
US (1) US20110236957A1 (fr)
WO (1) WO2010040062A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252843A1 (en) * 2010-11-22 2013-09-26 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Portl Method of making and using fluorescent-tagged nanoparticles and microarrays
WO2013036827A2 (fr) 2011-09-08 2013-03-14 The Regents Of The University Of California Métalloprotéases fongiques spécifiques et leurs utilisations
DE102011053541A1 (de) * 2011-09-12 2013-03-14 Nanospot Gmbh Marker zum optischen Nachweis der Bindung eines Biomoleküls und Verfahren zur Anwendung des Markers
CN102585801A (zh) * 2012-01-29 2012-07-18 上海交通大学 量子点-超支化聚醚纳米复合物一氧化氮荧光探针的制备方法
JP6175144B2 (ja) * 2012-12-04 2017-08-02 サイノファーム タイワン，リミティド 分子のプールの選択方法
FR3002180B1 (fr) 2013-02-18 2017-12-29 Arkema France Utilisation de copolyamide semi-aromatique pour le transport de fluide frigorigene
NL2010960C2 (en) * 2013-06-12 2014-12-15 Stichting Vu Vumc Molecular manipulation system and method.
US10124072B2 (en) * 2013-09-18 2018-11-13 Caliper Life Sciences, Inc. In-vivo reactive species imaging
GB2577292A (en) * 2018-09-20 2020-03-25 Sumitomo Chemical Co Light-emitting marker particles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417339B1 (en) * 1996-06-20 2002-07-09 Deutsches Krebsforschungzentrum Stiftung Des Offentlichen Rechts Dendrimers based on saccharides
US20050220714A1 (en) * 2004-04-01 2005-10-06 Susan Kauzlarich Agents for use in magnetic resonance and optical imaging

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604956B2 (en) * 2004-03-01 2009-10-20 Biotraces, Inc. Supersensitive immunoassays
US20070140974A1 (en) * 2005-12-15 2007-06-21 General Electric Company Targeted nanoparticles for magnetic resonance imaging
WO2007143076A2 (fr) * 2006-05-31 2007-12-13 Agency For Science, Technology And Research Nanoparticules et nanoparticules revêtues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417339B1 (en) * 1996-06-20 2002-07-09 Deutsches Krebsforschungzentrum Stiftung Des Offentlichen Rechts Dendrimers based on saccharides
US20050220714A1 (en) * 2004-04-01 2005-10-06 Susan Kauzlarich Agents for use in magnetic resonance and optical imaging

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GERHART J ET AL: "DNA dendrimers localize MyoD mRNA in presomitic tissues of the chick embryo", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 149, no. 4, 15 May 2000 (2000-05-15), pages 825 - 834, XP002434335, ISSN: 0021-9525 *
LOWE MARY ET AL: "Multiplexed, particle-based detection of DNA using flow cytometry with 3DNA dendrimers for signal amplification", CYTOMETRY, vol. 60A, no. 2, August 2004 (2004-08-01), pages 135 - 144, XP002562549, ISSN: 0196-4763 *
ONG K K ET AL: "Dendrimer enhanced immunosensors for biological detection", ANALYTICA CHIMICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 444, no. 1, 12 October 2001 (2001-10-12), pages 143 - 148, XP002495439, ISSN: 0003-2670 *
SCHNYDER ANITA ET AL: "Targeting of skeletal muscle in vitro using biotinylated immunoliposomes", BIOCHEMICAL JOURNAL,, vol. 377, no. 1, 1 January 2004 (2004-01-01), pages 61 - 67, XP002560984 *
WENG KEVIN C ET AL: "Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.", NANO LETTERS SEP 2008, vol. 8, no. 9, September 2008 (2008-09-01), pages 2851 - 2857, XP002562548, ISSN: 1530-6984 *

Also Published As

Publication number Publication date
US20110236957A1 (en) 2011-09-29
WO2010040062A2 (fr) 2010-04-08

Similar Documents

Publication Publication Date Title
WO2010040062A3 (fr) Réactifs de marquage de nanoparticules et leurs procédés d’utilisations
WO2011009539A8 (fr) CONJUGUÉS DE ε-POLYLYSINE ET LEUR UTILISATION
WO2010057114A3 (fr) Nanoparticules fonctionnalisées et procédés de formation et d'utilisation de celles-ci
EP2644194A3 (fr) Combinaisons de conjugué de médicament-anticorps anti-HER2 et de docétaxel
WO2006115633A3 (fr) Conjugue fluorescent de chlorotoxine et procede de visualisation intra-operative de cancer
IL191147A0 (en) Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2009092011A8 (fr) Anticorps obtenus par la cystéine pour conjugaison spécifique d'un site
WO2007098182A3 (fr) Colorants et conjugues fluorescents phosphonyles
WO2010081001A3 (fr) Fusions de gène récurrent dans le cancer
WO2009120247A3 (fr) Compositions de nanoparticules de lipides et procédés de préparation et d’utilisation de celles-ci
EP1835523B8 (fr) Microscope à électrons à contraste de phase
WO2006113679A3 (fr) Administration d'arnsi par compositions lipidiques neutres
WO2009120893A3 (fr) Conjugués polypeptide-polymère et procédés d’utilisation de ceux-ci
WO2012054525A3 (fr) Points polymères chromophores
WO2012048063A3 (fr) Composés de cyanine, conjugués et procédé d'utilisation
WO2007115265A3 (fr) Agents réactifs utiles pour synthétiser des oligonucléotides marqués à la rhodamine
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2010008519A3 (fr) Marqueurs diagnostiques in vitro comprenant des nanoparticules de carbone et trousses
WO2011084803A3 (fr) Agents colorants et leurs procédés d'utilisation
WO2009111586A3 (fr) Évolution autonome in vitro
WO2008139206A3 (fr) Agents optiques de formation d'image
WO2009108932A3 (fr) Sélection de ligands utiles pour le diagnostic et le traitement du cancer
IL206060A0 (en) Conjugates of anti-rg-1 antibodies, compositions comprising the same and uses thereof
WO2007041241A3 (fr) Compositions et procedes permettant la detection des interactions ligand-recepteur
WO2012007845A3 (fr) Procédé d'augmentation de l'effet d'une forme activée-potentialisée d'un anticorps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793281

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13122397

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09793281

Country of ref document: EP

Kind code of ref document: A2